# Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients

> **NCT00148850** · PHASE3 · TERMINATED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 130 (—)

## Conditions studied

- HIV-Associated Lipodystrophy Syndrome
- HIV Infections

## Interventions

- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT00148850
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 130 (—)
- **Last updated:** 2005-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148850, "Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00148850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*